Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222


The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI).

Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC, Petersen RC, Jack CR Jr, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (ADNI)†.

Front Aging Neurosci. 2013 Apr 1;5:11. doi: 10.3389/fnagi.2013.00011. eCollection 2013.


Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.


Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.

Liu Y, Tan L, Wang HF, Liu Y, Hao XK, Tan CC, Jiang T, Liu B, Zhang DQ, Yu JT; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurobiol. 2016 Sep;53(7):4539-47. doi: 10.1007/s12035-015-9388-7. Epub 2015 Aug 23.


APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.

Risacher SL, Kim S, Nho K, Foroud T, Shen L, Petersen RC, Jack CR Jr, Beckett LA, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (ADNI).

Alzheimers Dement. 2015 Dec;11(12):1417-29. doi: 10.1016/j.jalz.2015.03.003. Epub 2015 May 7.


ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.

Apostolova LG, Hwang KS, Kohannim O, Avila D, Elashoff D, Jack CR Jr, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2014 Jan 4;4:461-72. doi: 10.1016/j.nicl.2013.12.012. eCollection 2014.


Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.


Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.

Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2010 Mar;67(3):308-16. doi: 10.1002/ana.21953.


Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.

Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, Davatzikos C; Alzheimer's Neuroimaging Initiative.

Neuroimage Clin. 2013 Nov 28;4:164-73. doi: 10.1016/j.nicl.2013.11.010. eCollection 2014.


Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.

Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M.

Dement Geriatr Cogn Disord. 2009;27(5):458-64. doi: 10.1159/000216841. Epub 2009 May 7.


Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.

Desikan RS, McEvoy LK, Holland D, Thompson WK, Brewer JB, Aisen PS, Andreassen OA, Hyman BT, Sperling RA, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

AJNR Am J Neuroradiol. 2013 Mar;34(3):505-10. doi: 10.3174/ajnr.A3267. Epub 2012 Sep 13.


Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.

Wu KY, Liu CY, Chen CS, Chen CH, Hsiao IT, Hsieh CJ, Lee CP, Yen TC, Lin KJ.

Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1067-76. doi: 10.1007/s00259-015-3291-3. Epub 2016 Jan 7.


Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment.

Seo EH, Kim SH, Park SH, Kang SH, Choo IH; Alzheimer's Disease Neuroimaging Initiative.

J Korean Med Sci. 2016 Feb;31(2):286-95. doi: 10.3346/jkms.2016.31.2.286. Epub 2016 Jan 13.


Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.

Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1340-54. doi: 10.1016/j.neurobiolaging.2010.04.030. Epub 2010 Jun 8.


Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data.

Tosun D, Schuff N, Shaw LM, Trojanowski JQ, Weiner MW; Alzheimer's Disease NeuroImaging Initiative.

J Alzheimers Dis. 2011;26 Suppl 3:77-90. doi: 10.3233/JAD-2011-0006.


CSF Apo-E levels associate with cognitive decline and MRI changes.

Toledo JB, Da X, Weiner MW, Wolk DA, Xie SX, Arnold SE, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol. 2014 May;127(5):621-32. doi: 10.1007/s00401-013-1236-0. Epub 2014 Jan 3.


2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Green RC, Harvey D, Jack CR, Jagust W, Luthman J, Morris JC, Petersen RC, Saykin AJ, Shaw L, Shen L, Schwarz A, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jun;11(6):e1-120. doi: 10.1016/j.jalz.2014.11.001. Review.


Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.

Han MR, Schellenberg GD, Wang LS; Alzheimer's Disease Neuroimaging Initiative.

BMC Neurol. 2010 Oct 8;10:90. doi: 10.1186/1471-2377-10-90.


ApoE alleles and tau markers in patients with different levels of cognitive impairment.

Lavados M, Farías G, Rothhammer F, Guillon M, Mujica MC, Maccioni C, Maccioni RB.

Arch Med Res. 2005 Sep-Oct;36(5):474-9.


Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.

Biol Psychiatry. 2004 Nov 1;56(9):670-6.


Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.

Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW; Alzheimer's Disease Neuroimaging Initiative*.

Brain. 2015 Mar;138(Pt 3):772-83. doi: 10.1093/brain/awu367. Epub 2014 Dec 24.

Items per page

Supplemental Content

Support Center